|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Biomarkers and subtypes of deranged lipid metabolism in nonalcoholic fatty liver disease显示文摘Nonalcoholic fatty liver disease(NAFLD)is a heterogeneous and complex disease that is imprecisely diagnosed by liver biopsy.NAFLD covers a spectrum that ranges from simple steatosis,nonalcoholic steatohepatitis(NASH)with varying degrees of fibrosis,to cirrhosis,which is a major risk factor for hepatocellular carcinoma.Lifestyle and eating habit changes during the last century have made NAFLD the most common liver disease linked to obesity,type 2 diabetes mellitus and dyslipidemia,with a global prevalence of 25%.NAFLD arises when the uptake of fatty acids(FA)and triglycerides(TG)from circulation and de novo lipogenesis saturate the rate of FAβ-oxidation and verylow density lipoprotein(VLDL)-TG export.Deranged lipid metabolism is also associated with NAFLD progression from steatosis to NASH,and therefore,alterations in liver and serum lipidomic signatures are good indicators of the disease’s development and progression.This review focuses on the importance of the classification of NAFLD patients into different subtypes,corresponding to the main alteration(s)in the major pathways that regulate FA homeostasis leading,in each case,to the initiation and progression of NASH.This concept also supports the targeted intervention as a key approach to maximize therapeutic efficacy and opens the door to the development of precise NASH treatments. | José M Mato Cristina Alonso Mazen Noureddin Shelly C Lu | 2019 | World Journal of Gastroenterology2019，25，24： | 19 |
| 2 | Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review显示文摘BACKGROUND S-adenosylmethionine(AdoMet)is a metabolically pleiotropic molecule used to treat intrahepatic cholestasis(IHC)and chronic liver diseases.While the efficacy of AdoMet has been demonstrated previously,it has not been systematically investigated within the early weeks of treatment.AIM To systematically review the early treatment efficacy of AdoMet in adult patients with IHC.METHODS Studies reporting the efficacy of intravenous,intramuscular,or oral forms of AdoMet within 8 wk of treatment initiation were considered;three randomized and six non-randomized studies were eligible for inclusion(PROSPERO registration number CRD42018090936).Of the three randomized studies,two were double-blind and placebo-controlled,and one was comparator-controlled with unclear blinding and a relatively high risk of bias.Mean serum levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),alkaline phosphatase(ALP),and gamma-glutamyl transferase(γGT)following AdoMet treatment vs placebo,comparator,or baseline were summarized to determine differences in liver enzymes.Changes in patient-reported clinical symptoms of cholestasis were also summarized.RESULTS Both placebo-controlled randomized studies reported significant reductions in serum ALT levels with AdoMet vs placebo within 2 wk.One of these also reported significant ALP reductions,and the other reported significant AST andγGT reductions within 2 wk.The comparator-controlled randomized study,which had a number of notable limitations,reported significant reductions in serum ALT and AST levels with AdoMet vs potassium magnesium aspartate within 4 wk,but not within2 wk.All of the non-randomized studies(4/4)that investigated ALT,AST,ALP and/orγGT reported significant reductions in at least two of these parameters within 2 wk.Of the five studies that evaluated fatigue,reductions were observed within 2 wk in one randomized and two nonrandomized studies.The remaining two non-randomized studies reported improvements in fatigue within 6 and 8 wk.Of the four studies reporting symptoms of depression,two non-randomized studies observed improvements within 2 wk and the other two observed improvements within 17 d and 8 wk.CONCLUSION Data from both randomized and non-randomized studies suggest that AdoMet improves some biochemical liver parameters and symptoms of cholestasis within 2 wk,with further improvements observed in some studies after 4 and 8 wk of treatment. | Mazen Noureddin Suntje Sander-Struckmeier JoséM Mato | 2020 | World Journal of Hepatology2020，12，2： | 8 |
| 3 | Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals显示文摘AIM To determine steatosis and fibrosis prevalence in hepatitis C patients after a sustained virological response achieved with direct-acting antivirals.METHODS Transient elastography with controlled attenuation parameter(CAP) was used to assess hepatic steatosis post-sustained virological response(SVR);the CAP technology was not available in the United States at study initiation.Liver stiffness/fibrosis was measured before and 47 wk after treatment completion.Patients with genotype 3 and patients with cirrhosis were excluded.RESULTS One hundred and one patients were included in the study.Post-SVR there were decreases from baseline in alanine aminotransferase(ALT)(63.1 to 17.8 U/L),aspartate aminotransferase(51.8 to 21.5 U/L) and fibrosis score(7.4 to 6.1 k Pa)(P < 0.05).Post-SVR,48 patients(47.5%) had steatosis on CAP;of these,6.25% had advanced fibrosis.Patients with steatosis had higher body mass index(29.0 vs 26.1 kg/m2),glucose(107.8 vs 96.6 mg/d L),ALT(20.4 vs 15.3 mg/d L),CAP score(296.3 vs 212.4 d B/m) and fibrosis score(7.0 vs 5.3 k Pa);P < 0.05.Interestingly,compared to baseline,both patients with and without steatosis had change in fibrosis score post-SVR(7.7 k Pa vs 7.0 k Pa and 7.0 k Pa vs 5.3 k Pa);alternatively,(P < 0.05) and therefore patients with steatosis continued to have clinically significant stiffness(≥ 7 k Pa).CONCLUSION Fatty liver is very common in hepatitis C virus(HCV) patients post-SVR.These patients continue to have elevated mean fibrosis score(≥ 7 k Pa) compared to those without fatty liver;some have advanced fibrosis.Long term follow up is needed to assess steatosis and fibrosis in HCV patients post-SVR. | Mazen Noureddin Micaela M Wong Tsuyoshi Todo Shelly C Lu Arun J Sanyal Edward A Mena | 2018 | World Journal of Gastroenterology2018，24，11： | 6 |
| 4 | A data driven failure prognostics method based on mix-ture of gaussians hidden markov models显示文摘 | Tobon-Mejia D A Kamal M Noureddine Z | 2012 | IEEE Transactions on Reliability2012，61，2： | 1 |
| 5 | Bioactive Triterpene Derivatives from Latex of Two Euphorbia Species显示文摘 | NOUREDDINE M AHMED B MARIA B | 2008 | Phytochemistry2008，69，： | 1 |
| 6 | Ocular toxicityin low-dose tamoxifen: a prospective study显示文摘 | Bashshur Z Seoud M | 1999 | Eye1999，13，： | 1 |
| 7 | Analysis of current crowding effects in multiturn spiral inductors显示文摘 | Kuhn William B Ibrahim Noureddin M | 2001 | IEEE trans mtt2001，49，1： | 1 |
| 8 | Right intracardiac thrombus in Behcet's disease显示文摘 | Noureddine M Charei N Drighil A | 2004 | Arch Mal Coeur Vaiss2004，97，9： | 1 |
| 9 | An authentication model towards cloud federation in the enter- prise 显示文摘 | Noureddine M Bashroush R | 2013 | Journal of Systems and Software2013，86，9： | 1 |
| 10 | Detection by 32P- postlabelling of 8-oxo-7, 8-dihydro-2-deoxyguanosine in DNA as biomarker of microcystin-LR and nodularin-induced DNA damage in vitro in primary cultured rat hepatocytes and in vivo in rat liver显示文摘 | Imed M Noureddine B Marie J | 2004 | Mutat Res2004，564，1： | 1 |
| 11 | An authentication model towards cloud federation in the enter- prise 显示文摘 | Noureddine M Bashroush R | 2013 | Joumal of Systems and Software2013，86，9： | 1 |
| 12 | Mutationsin the pleckstrin homology domain of dynamin 2 causedominant intermediate Charcot-Marie-Tooth disease显示文摘 | Züchner S Noureddine M Kennerson M | 2005 | Nat Genet2005，37，3： | 1 |
| 13 | Combined effects ofIL-8 and CXCR2 gene polymorphisms on breast cancer suscepti-bility and aggressiveness显示文摘 | Kaouther S Wijden M Noureddine B | 2010 | BMC Cancer2010，10，： | 1 |
| 14 | Pulmonary atery smooth muscle cee senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung disease显示文摘 | Noureddine H Gary-Bobo G Alifano M | 2011 | Circ Res2011，109，5： | 1 |
| 15 | Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis显示文摘 | Noureddin M Wright EC Alter HJ | 2013 | Hepatology2013，58，5： | 1 |
| 16 | A mix method of knowledge capitalization in maintenance显示文摘 | IVANA R BRIGITTE C M NOUREDDINE Z | 2008 | Journal of Intelligent Manufacturing2008，19，3： | 1 |
| 17 | Response to signs and symptoms of acute coronary syndrome:differences between lebanese men and women显示文摘 | Noureddine S Arevian M Adra M | | 0，，01： | 1 |
| 18 | Changes in S-adenosylmethionine and GSH homeostasis during endotoxemia in mice 显示文摘 | Ko K Yang H Noureddin M | 2008 | Lab Invest2008，88，10： | 1 |
| 19 | Association between the neuron-specific RNA- binding protein ELAVL4 and Parkinson disease 显示文摘 | NOUREDDINE M A QIN X J OLIVEIRA S A | 2005 | Hum Genet2005，117，1： | 1 |
| 20 | 显示文摘 | ARMAND S NOUREDDINE M | 2005 | Composites2005，36，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员